D.W. Cescon

875 citations
8 papers · 693 · 1 hit paper · h-index 3

Impact in

  • Oncology top 5%
    • Cancer Immunotherapy and Biomarkers
    • PARP inhibition in cancer therapy
    • Cancer Cells and Metastasis
    • HER2/EGFR in Cancer Research
    • Breast Cancer Treatment Studies

Papers in

D.W. Cescon

4 papers receiving 676 citations

D.W. Cescon's Hit Papers

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study 2018 · 681 citations
6810+2+5Years since publication200400600

Peers

D.W. Cescon
Comparison fields: 5 of 39
  • Oncology 462
  • Cancer Research 251
  • Immunology 44
  • Pulmonary and Respiratory Medicine 46
  • Biological Psychiatry 1
Replace D. Toppmeyer with:
D. Toppmeyer United States
A. Swat Switzerland
Paula Podolski Croatia
Keo Tabane Germany
Larysa Ryvo Israel
Rin Ogiya Japan
Amanda Zucker United States
M.A. Vicente Conesa Spain
Dennis Poel Netherlands
D.W. Cescon relative to D. Toppmeyer United States D. Toppmeyer's profile →
Citations per field
00.5×1.5×
D. Toppmeyer · 1×
Citations per year

Countries citing papers authored by D.W. Cescon

Since Specialization
Citations

This map shows the geographic impact of D.W. Cescon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.W. Cescon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.W. Cescon more than expected).

Fields of papers citing papers by D.W. Cescon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.W. Cescon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.W. Cescon. The network helps show where D.W. Cescon may publish in the future.

Co-authors

The 25 scholars most cited alongside D.W. Cescon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D.W. Cescon Line = papers co-authored together D.W. Cescon links everyone, so they are left out of the graph.

All Works

8 of 8 papers shown
#Work
1
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Hit paper breakdown →
2018681
2 20247
3 20253
4 20251
5 20261
6 20260
7 20260
8 20260

About D.W. Cescon

D.W. Cescon is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Oncology, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 8 papers that have together received 693 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (6 papers), Advanced Breast Cancer Therapies (4 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer Genomics and Diagnostics (2 papers) and HER2/EGFR in Cancer Research (1 paper). The work is most often cited by research in Oncology (462 citations), Cancer Research (251 citations), Immunology (44 citations), Pulmonary and Respiratory Medicine (46 citations) and Biological Psychiatry (1 citation). D.W. Cescon has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Komal L. Jhaveri, Aditya Bardia, Barbara Pistilli, Junji Tsurutani, Michelino De Laurentiis, Hope S. Rugo, Masaya Hattori, Binghe Xu, Kevin M. Kalinsky and Seock‐Ah Im. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact